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Abstract 
Review on t(9;11)(p21;q23), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Acute myeloid leukemia (AML). 
Phenotype/cell stem origin 
Most often found in acute monocytic and 
myelomonocytic leukaemias, although occasionally 
also seen in AML with or without maturation (WHO 
2008).  
M5 most often (especially M5a, M4); both found in 
de novo and therapy related AML with 
antitopoisomerase II drugs (epipodophyllotoxins, 
anthracyclins, actinomycin D).  
Immunophenotype typically shows positivity for 
CD11, CD13, CD15 and CD33, but less often shows 
positivity for CD14, CD34 and lymphoid markers. 
Epidemiology 
May occur at any age, but is more common in 
children, being present in 5-12% of paediatric and 1-
2% of adult AML, and equally common in males and 
females. 
Clinics 
Organomegaly, frequent central nervous system 
(CNS) involvement, especially in de novo cases; no 
preceding myelodysplastic phase, unlike classic 
therapy related AML with chromosome 5 and/or 7 
involvement, short interval from initial drug therapy 
(may even be of 1-2 yrs). Patients may present with 
disseminated intravascular coagulation and may 
have tissue infiltration. 
Cytology 
Absence of trilineage dysplasia, unlike classic 
therapy related AML. 
Prognosis 
Survival is described as poor to intermediate, being 
superior to AML with other KMT2A translocations. 
Cytogenetics 
Cytogenetics morphological 
May easily be overlooked. Previously described as 
t(9;11)(p22;q23) based on band estimation, but 
nowadays it is known that MLLT3 is located in 
9p21.3 based on molecular positioning. 
Cytogenetics molecular 
FISH or RT-PCR is indicated in cases with poor 
chromosome morphology or in cases where the 
translocation is expected in cases based on 
morphology, immunophenotype or clinical 
presentation. 
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t(9;11)(p21;q23) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen (top 2), Courtesy Diane H Norback, Eric B 
Johnson, and Sara Morrison-Delap, UW Cytogenetic Services (middle 2 and bottom 2); R-banding (right): top: - Courtesy 
Pascale Cornillet-Lefebvre and Stéphanie Struski, center top: t(9;11)+der(9)t(9;11) - Courtesy Christiane Chharrin; bottom 2: - 
Courtesy Hossein Mossafa. FISH (left) - Courtesy Pascale Cornillet-Lefebvre and Stéphanie Struski. The probe is MLL; one 
signal is on the normal 11, one signal on the der(11), and one signal (arrow) on the der(9); FISH (right) - Courtesy Hossein 
Mossafa (AN: abnormal). 
 
Additional anomalies 
None in 70% of cases, +8 in 20%, less frequently: 
additional trisomies of chromosome 6, 19 or 21. 
Variants 
Complex 3 way translocations t(9;11;Var) involving 
a (variable) third chromosome and insertions have 
been described, and showed that der(11) is the 
crucial on 
Genes involved and 
proteins 
MLLT3 (myeloid/lymphoid or mixed-
lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 3) 
Location 
9p21.3 
Protein 
Contains a nuclear targeting sequence; 
transcriptional activator; nuclear localisation. 
KMT2A (myeloid/lymphoid or mixed 
lineage leukemia) 
Location 
11q23.3 
Protein 
Contains two DNA binding motifs (a AT hook, and 
Zinc fingers), a DNA methyl transferase motif, a 
bromodomain; transcriptional regulatory factor; 
nuclear localisation. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' KMT2A- 3' MLLT3; variable breakpoints. 
Fusion protein 
Description 
N-term -- AT hook and DNA methyltransferase from 
KMT2A (1444 amino acids) fused to the 192  
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C-term amino acids from MLLT3 (as breakpoints 
are variable, this is only an exemple); 180 kDa. 
Expression / Localisation 
Nuclear localisation. 
To be noted 
You may also have a glance at 11q23 
rearrangements, which gives an overview of related 
diseases. 
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